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One approach to the development of an HIV vaccine is to design a protein template which can present
gp120 epitopes inducing cross-neutralizing antibodies. To select a V3 sequence for immunogen design,
we compared the neutralizing activities of 18 anti-V3 monoclonal antibodies (mAbs) derived from
Cameroonian and Indian individuals infected with clade AG and C, respectively. It was found that V3
mAbs from the Cameroonian patients were signiﬁcantly more cross-neutralizing than those from India.
Interestingly, superior neutralizing activity of Cameroonian mAbs was also observed among the nine
VH5-51/VL lambda genes encoding V3 mAbs which mediate a similar mode of recognition.
This correlated with higher relative binding afﬁnity to a variety of gp120s and increased mutation
rates in V3 mAbs from Cameroon. These results suggest that clade C V3 is probably weakly
immunogenic and that the V3 sequence of CRF02_AG viruses can serve as a plausible template for
vaccine immunogen design.
& 2013 Elsevier Inc. All rights reserved.Introduction
In light of the continuing worldwide spread of HIV-1 infection,
it is accepted that a vaccine would be the most effective
prophylaxis, although the genetic variation of the virus remains
a major challenge. A certain optimism for designing an efﬁcient
vaccine was recently raised by the results from the RV144 clinical
vaccine trial, which suggested that anti-HIV-1 antibodies (Abs)
played a protective role (Rerks-Ngarm et al., 2009). Indeed, it was
revealed that high titers of plasma anti-V1/V2 Abs correlated
inversely with the rate of HIV-1 infection (Haynes et al., 2012).
The neutralizing antibody response in the vaccine recipients was
weak and did not correlate with the rate of infection but it was
suggested that it can be partially protective against HIV-1
(Monteﬁori et al., 2012).
One concept for an HIV vaccine is to design a template with a
set of immunogens representing various epitopes in the envelope.ll rights reserved.
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rny).Such epitopes could include the V1/V2 regions as well as the V3
loop which is known to induce cross-clade neutralizing Abs (Corti
et al., 2010; Hioe et al., 2010; Pantophlet et al., 2007; Scheid et al.,
2009;2011). The contribution of anti-V3 Abs in protection against
HIV-1 infection was documented by passive immunization
experiments in animal models (Andrus et al., 1998; Emini et al.,
1992; Watkins et al., 2011). Studies in vitro in several laboratories
showed that the human V3 mAbs can neutralize the majority of
tier 1 pseudoviruses (psVs) and some tier 2 viruses but their
cross-clade neutralizing activity is relatively limited (Corti et al.,
2010; Hioe et al., 2010; Pantophlet et al., 2007; Scheid et al.,
2009;2011). Moreover, it was demonstrated in animal experi-
ments that V3 immunogens can induce cross-clade neutralizing
antibodies (Letvin et al., 2001; Zolla-Pazner et al., 2011).
The question still remains which V3 structure would be the
most effective in inducing cross-neutralizing Abs. It was shown
previously that anti-V3 mAbs derived from individuals infected
with non-B clade viruses were more cross-reactive than clade B-
derived V3 mAbs (Gorny et al., 2006). This appears to be due to
the fact that the relatively conserved V3 motif GPGR in clade B
viruses focuses the immune response on the positively charged
Arg (R) and thus narrows the cross-reactivity of the responding
Table 1
Human anti-V3 and control mAbs used for the study.
No. mAbsa Site Isotype Subtype of the
infecting virusb
Country of
origin
Reference
1 3869 V3 IgG1 l Nd Cameroon Gorny et al.
(2009)
2 4210 V3 IgG1 l Nd Cameroon This study
3 3074 V3 IgG1 l CRF02_AG Cameroon Gorny et al.
(2006)
4 3881 V3 IgG1 k CRF02_AG Cameroon Gorny et al.
(2009)
5 4508 V3 IgG1 k CRF02_AG Cameroon This study
6 2557 V3 IgG1 l CRF02_AG Cameroon Gorny et al.
(2004)
7 2558 V3 IgG1 l CRF02_AG Cameroon Gorny et al.
(2004)
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induction of Abs to other conserved elements of the V3 region
(Jiang et al., 2010). The non-B clade viruses, with the GPGQ motif,
are a very heterogeneous group, involved in 85% of global HIV-1
infection with the most dominant being clade C, followed by clade
A (Osmanov et al., 2002).
In this study we compared the neutralizing and binding
activity of two panels of anti-V3 mAbs derived from subjects
living in Cameroon and India and infected with non-B clade
viruses containing the envelope (Env) sequence corresponding
to clade A, mainly CRF02_AG, and clade C, respectively. The
results showed that the mAbs from the Cameroonian patients
were signiﬁcantly more cross-neutralizing than those from India,
suggesting that the V3 structure and sequence of CRF02_AG
viruses would be better for immunogen design.8 3019 V3 IgG1 l CRF02_AG Cameroon Gorny et al.
(2006)
9 3694 V3 IgG1 l H Cameroon Gorny et al.
(2009)
10 4139 V3 IgG1 l C India This study
11 3791 V3 IgG1 k C India Gorny et al.
(2009)
12 4121 V3 IgG1 l C India Gorny et al.
(2009)
13 3904 V3 IgG1 k C India Gorny et al.
(2009)
14 3906 V3 IgG1 l C India Gorny et al.
(2009)
15 4490 V3 IgG1 l Nd India This study
16 4022 V3 IgG1 l C India Gorny et al.
(2009)
17 4025 V3 IgG1 l Nd India Gorny et al.
(2009)
18 4487 V3 IgG1 l Nd India This study
Controls:
447-
52D
V3 IgG3 l B USA Gorny et al.
(1993)
1418c B19 IgG1 k N/A USA Gigler et al.
(1999)
Nd—Not determined.
a Each mAb is derived from one HIV-1 infected individual (except 1418 which
was produced from a subject carrying anti-parvovirus B19 serum Abs) living in the
depicted countries.
b The subtype of the infecting HIV-1 was determined in our laboratory by
sequencing the envelope fragment (C2-V5) from the donor plasma virus.
c Human mAb 1418 is speciﬁc against parvovirus B19 and it serves here as
negative control.Results
Human anti-V3 mAbs
A panel of 18 anti-V3 mAbs derived from individuals infected
with non-B clade HIV-1 includes ﬁve new anti-V3 mAbs, not yet
described, generated from Cameroonian (mAbs 4210 and 4508)
and Indian patients (mAbs 4139, 4487 and 4490) (Table 1). These
ﬁve new mAbs belong to subclass IgG1 with four l and one k light
chains (Table 1). The remaining 13 V3 mAbs have been previously
described and characterized (Table 1).
Immunoglobulin gene usage
The variable fragment of the heavy (VH) and light (VL) chain
genes were sequenced and analyzed using the IMGT system to
determine the immunoglobulin (Ig) gene usage and percentage of
mutations. A biased usage of VH genes was observed, as 9 of 18
(50%) anti-V3 mAbs were encoded by the VH5-51 gene segment:
four mAbs developed from Cameroonian and ﬁve from Indian
patients; however, these mAbs used different alleles, mainly n03
and n01, respectively (Table 2). Five other mAbs used VH1 family
genes while three mAbs, 3074, 3881 and 4508 used one particular
gene segment, VH4-59. The VH3 family genes, which are the most
commonly used by Abs derived from healthy individuals (Tiller
et al., 2007), were represented only by one V3 mAb which used
the VH3-30 gene (Table 2).
Usage of the light chain genes was also biased toward lambda
genes which were used by 14 of 18 mAbs (Table 2) while in mAbs
derived from healthy subjects there is dominance of k over l light
chain genes (Tiller et al., 2007). Among lambda VL genes, the most
frequently used was the VL3-1 gene in 8 of 14 mAbs (57%), which
mainly paired with VH5-51 gene (6 of 9 pairs using VH5-51 gene).
The amino acid sequence of the complementarity-determining
region 3 (CDR) of the heavy chain (H3) and light chain (L3) was
unique for each mAb (Table S1).
Neutralization of pseudoviruses by anti-V3 mAbs derived from
Cameroonian and Indian HIV-1 infected patients
A panel of 18 anti-V3 antibodies derived from the Cameroo-
nian and Indian HIV-1 infected subjects and a control mAb 1418
(anti-parvovirus B19) were tested with 41 pseudotyped viruses
from clade A, B, C and AG for their neutralizing activity. Twenty-one
of 41 viruses tested were found to be neutralized by this panel of
V3 mAbs with a 50% inhibitory concentration (IC50)o50 mg/ml
(Table 3). The remaining 20 psVs were not neutralized at an IC50
below 50 mg/ml (data not shown); all but one of these were tier
2 viruses (HO29.12, HO30.7, HO35.18, HO61.14, WITO4160.33,SC42661.8, TRO.11, AC10.0.29, THRO4156.18, CAAN5342.A2,
PVO.4, TRJO4551.58 [clade B], CAP45.2.00.G3, Du156.12,
Du172.17, Du422.1, ZM53M.PB12, ZM135M.PL10, ZM214M.PL15,
ZM249M.PL1 [clade C]).
The V3 mAbs neutralized both sensitive tier 1 and the more
resistant tier 2 psVs; however, the mAbs displayed different
patterns of activity with these two categories of psVs. For
example, most tier 1 viruses were neutralized at o1 mg/ml, while
most of the tier 2 viruses required 410 mg/ml of the mAbs to
reach 50% neutralization. In terms of frequency, 106 of 198 (53%)
tier 1 psVs/mAb combinations showed neutralizing activity while
only 30 of 180 (16%) tier 2 psVs/mAb combinations showed
neutralization (po0.001) (Table 3).
Interestingly, nine mAbs from the Cameroonian patients neu-
tralized 21 psVs signiﬁcantly more potently than the nine mAbs
from the Indian patients by comparing their IC50 values
(p¼0.001). The signiﬁcantly more potent neutralizing activity of
the anti-V3 mAbs from the Cameroonian patients was observed
separately for (a) tier 1 (n¼11 psVs, po0.01), (b) tier 2
(n¼10 psVs, po0.0001), (c) clade B (n¼12 psVs, p¼0.002), and
(d) non-B clade viruses (n¼9 psVs, p¼0.01). Statistical signiﬁcance
was determined using the Chi-Squared test.
Table 2
Analysis of immunoglobulin gene usage and percent mutations in the variable
fragment of human anti-V3 mAbs.
mAba IGHVb IGHJb mut (%)c IGLVb IGLJb mut (%)c
3869 1-f*01 4*02 8.3 L3-1*01 2*01/3*01 8.6
4210 1-f*01 3*02 5.6 L3-1*01 3*02 4.3
3074 4–59*01 3*01 5.9 L1-51*02 2*01/3*01 5.3
3881 4–59*01 3*02 11.2 K3-15*01 1*01 5.4
4508 4–59*01 4*02 4.6 K4-1*01 3*01 4.7
2557 5–51*01 3*01 14.2 L3-1*01 3*02 14.0
2558 5–51*03 4*02 7.3 L3-1*01 2*01/3*01 5.7
3019 5–51*03 3*01 5.9 L3-1*01 2*01/3*01 9.7
3694 5–51*03 1*01 18.1 L3-1*01 2*01/3*01 11.5
4139 1–8*01 4*02 6.6 L2-14*01 2*01/3*01 6.6
3791 1–18*01 4*02 12.2 K1-3301 4*01 4.3
4121 1–18*01 4*02 5.2 L1-44*01 1*01 1.4
3904 3–30*03 4*03 5.9 K1-39*01 3*01 5.0
3906 5–51*01 3*02 7.3 L3-1*01 2*01/3*01 9.7
4490 5–51*01 4*02 4.5 L3-1*01 2*01/3*01 5.0
4022 5–51*01 5*02 11.8 L3-10*01 3*02 7.9
4025 5–51*01 6*02 3.8 L3-10*01 1*01 4.7
4487 5–51*03 4*02 8.3 L1-51*02 2*01/3*01 5.6
a The ﬁrst nine mAbs are derived from Cameroon while the second nine mAbs
are from India HIV-1 infected subjects, separated by a space.
b Immunoglobulin genes and alleles (n) were determined using the nucleotide
sequence of the variable fragments of mAbs analyzed by IMGT system.
c mut — percent of mutation in IGHV and IGLV indicate the difference in
nucleotide sequence between the tested mAbs and corresponding germline.
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83 of 189 psVs/mAb combinations (44%) of the mAbs from the
Cameroonian patients displayed neutralization compared to 53 of
189 psVs/mAb combinations (28%) displayed by the mAbs from
the Indian patients (Table 3).
To understand the difference in the neutralizing activity we
analyzed (a) Ig gene usage, (b) percentage of mutations, (c)
relative binding afﬁnity and (d) the epitopes of the mAbs derived
from the Cameroonian and Indian patients.
Neutralization of VH5-51- and non-VH5-51-derived anti-V3 mAbs
Nine of 18 V3 mAbs, including four from Cameroonian and ﬁve
from Indian patients, used the VH5-51 gene paired with VL
lambda genes; six VL3-1, two VL3-10 and one VL1-51 gene
(Table 2). Using the neutralization data from Table 3, statistical
analysis revealed that the VH5-51-derived V3 mAbs from the
Cameroonian patients were signiﬁcantly more potent than the
corresponding mAbs from the Indian patients (p¼0.006, Table
S2). Similarly, we analyzed the remaining mAbs encoded by
non-VH5-51 genes including the VH1 family, the VH4-59 and
VH3-30 genes. It was also found that the mAbs from the Camer-
oonian compared to Indian patients were signiﬁcantly more potent
in neutralization of psVs (p¼0.01, Table S3) as determined using the
Chi-Squared test, suggesting that the neutralizing efﬁciency of V3
mAbs from the Cameroonian patients may be independent of their
VH gene usage.
Percentage of mutations in the heavy and light chain genes of anti-V3
mAbs
The percentage of point mutations in the nucleotide sequences
of the variable (V) region of the heavy and light chain genes was
determined by alignment with the corresponding germline genes
using the IMGT system. The percentage of mutations varied for
the VH genes from 3.8% to 18.1%, with a mean of 8.1%, while for
VL genes varied from 1.4% to 14.0% with a mean of 6.6% (Table 2).
We compared the percentage of mutations in the heavy and lightchain genes combined together using the Student’s t-test; the
mean percentage for mAbs derived from the Cameroonian
patients was higher than for those from the Indian patients,
16.7% versus 12.8%, but the difference was not signiﬁcant
(p¼0.20) (Table S4).
The percentage of mutations was also analyzed separately for
VH5-51-encoded V3 mAbs and was higher (although not signiﬁ-
cantly) for mAbs derived from the Cameroonian patients compared
to those from the Indian patients, 21.6% versus 13.7% (p¼0.13),
respectively. The non-VH5-51 mAbs, which used the VH1 family,
VH4-59 and VH3-30 genes, had only a slightly higher percentage of
mutations amongst the mAbs from Cameroon vs. those from India,
12.7% and 11.8% (p¼0.71) (Table S4). These results indicate that the
percentage of mutations is higher among the V3 mAbs from
Cameroon compared to those from India, especially in VH5-51-
derived mAbs, but statistically comparable.
We analyzed the possible association between the percentage
of mutations in the 18 V3 mAbs and the number of neutralized
pseudoviruses and we found only a trend but not a signiﬁcant
correlation (p¼0.2668 for all psVs and p¼0.1927 for tier 2 psVs;
Fig. S1). This study has some limitations because the CDR3
sequence of the heavy chain (CDR H3) is not included in the
analysis of mutation rate due to lack of the corresponding germ-
line sequence.
Binding of anti-V3 mAbs to recombinant gp120s
The lower neutralizing activity of the V3 mAbs from the Indian
patients compared to those from the Cameroonian patients could
be related to lower binding afﬁnity. To test this hypothesis, all 18
anti-V3 mAbs were tested for their reactivity to 18 recombinant
gp120s with sequences from one clade A, seven clade C and 10
clade B viruses (Table 4). Twelve gp120s corresponded to the
respective psVs tested in the neutralization assay, but only four of
these psVs (SF162.LS, ZM197M.PB7, JRFL.JB and REJO4541.67)
were neutralized, as shown in Table 3. Although recombinant
gp120 cannot mimic the native trimeric structure of the envelope
which is targeted by the mAb in order to neutralize, binding
indicates the presence of the epitope in the virus envelope. A
representative binding pattern of mAbs to gp120s of clade C, A
and B supported these data (Fig. S2A–D).
The binding experiments showed that the anti-V3 mAbs were
able to bind all the clade C and one clade A gp120s and the only
difference between the mAbs from Cameroon and India was
observed in binding to clade B gp120s (Table 4). Particularly,
none of the mAbs from the Indian panel was able to bind two of
the clade B gp120s (CDC451 and 11.B11.1550) while four mAbs
from the Cameroonian panel showed reactivity (Table 4, Fig. S2D).
The relative afﬁnities measured by 50% of maximal binding
were higher for Cameroonian versus Indian V3 mAbs; for binding
to clade C and A gp120s the difference was not signiﬁcant
(p¼0.529) while for binding to clade B gp120s the difference
was highly signiﬁcant (p¼0.0002, Chi-Squared test) (Table 4).
Study of the V3 epitopes based on mAbs binding to gp120s
The binding experiments revealed that clade C and clade A gp120s
were recognized by all V3 mAbs in contrast to clade B gp120s that
was reactive with majority of mAbs. Three mAbs, 4508, 3791 and
3904 (derived from one Cameroonian and from two Indian patients)
did not bind to any of the clade B gp120s which differ from clade C
and A gp120s by residue Arg (R) at position 315 in the V3 region
(Tables 4 and 5) suggesting that the epitope of these mAbs include
the tip of the V3 loop. The remaining 15mAbs were tolerant for
changes in R/Q/K residues at position 315, suggesting that this residue
is not an important component of the epitope. Furthermore, themAbs
Table 3
Neutralization of pseudoviruses by anti-V3 mAbs derived from Cameroonian and Indian HIV-1 infected individualsa.
No. Virus ID Tier Clade Cameroon mAbs India mAbs
2558 2557 3019 3694 3869 4210 3074 4508 3881 3906 4022 4487 4490 4025 3791 4121 4139 3904 1418
5-51 5-51 5-51 5-51 1-f 1-f 4-59 4-59 4-59 5-51 5-51 5-51 5-51 5-51 1-18 1-18 1-8 3-30
1 MW965.26 1A C o0.4 o0.4 o0.4 o0.4 o0.4 o0.4 o0.4 o0.4 o0.4 o0.4 o0.4 o0.4 o0.4 o0.4 o0.4 o0.4 o0.4 o0.4 –
2 271-11 1B AG 2 3.6 5.5 19.5 0.9 1.2 o0.4 o0.4 – 0.4 3.2 3.1 – 3.9 o0.4 17.9 1.3 3.4 –
3 DJ263.8 1B A 1.9 – – 4.4 2.2 – o0.4 o0.4 o0.4 3.1 0.7 – 9.1 0.8 o0.4 6.2 0.6 1.7 –
4 25710-2.43 1B C – – – – – – 11.7 14.5 46 – – – – – 43 – – – –
5 242-14 1B AG – – – – – – 49.9 – – – – – – – – – – – –
6 SF162.LS 1A B o0.4 o0.4 o0.4 o0.4 o0.4 o0.4 o0.4 – – 18.4 o0.4 3.7 3.2 o0.4 – 12 25.8 – –
7 Bx08.16 1B B 0.8 0.4 0.8 6.9 1.1 3.9 3.3 – – – 10.6 2.8 2.8 – – 32.3 23.7 – –
8 BaL.26 1B B 0.4 o0.4 0.7 1.4 1.4 3.7 5.2 – – – – 4.7 4 – – 37.8 – – –
9 SS1196.1 1B B 2.6 2.6 5.2 25.5 1 10.7 7.5 – – – 7.8 14.4 21.8 – – – – – –
10 BZ167.12 1B B 0.5 – – 2.5 – 30.2 – – – 0.4 – – – – – 4 – – –
11 HXB2.DG 1B B 45.4 – – – – – – – – 9.4 – – – – – – – – –
12 ZM109F.PB4 2 C 24.9 25.3 – – 14.5 15.7 6.6 2.5 – 5.1 26.6 – – 49.1 8.7 – – – –
13 ZM233M.PB6 2 C – – – – 44.3 – 49.7 – – 37.8 – – – – – – – – –
14 ZM197M.PB7 2 C – – – – – – – – – – – 16.7 – – – – – – –
15 CAP210.2.00 2 C – – – – – – 39.5 – – – – – – – – – – – –
16 6535.3 2 B 32.6 2.9 – – 1.6 – – – – – – – – – – – – – –
17 QH0692.42 2 B 46.1 41.8 – – 9.9 – – – – – – – – – – – – – –
18 HO31.7 2 B 13.9 5.9 13.2 – – – – – – – – – – – – – – – –
19 JRFL.JB 2 B 30.4 21.2 47.5 – – – – – – – – – – – – – – – –
20 REJO4541.67 2 B – 14.1 – – 49.6 – – – – – – – – – – – – – –
21 RHPA4259.7 2 B – – – – 26.1 – – – – – – – – – – – – – –
a All 18 mAbs were tested against 41 pseudotyped viruses using the TZM-bl cell assay; only 21 viruses, reactive with at least one mAb are shown in the table. Nine mAbs from each group (Cameroon and India) are shown
with sample IDs (4 digit numerical) at the top of each column and immunoglobulin VH gene usage in the next row below. Monoclonal Abs encoded by VH5-51 gene are bold. The space separates tier 1 from tier 2 pseudotyped
viruses. The IC50 values which indicate the amount of mAbs (mg/ml) needed for 50% neutralization are shown in each cell; they were estimated from the titration curves. The IC50 450 ug/ml () have been omitted. Monoclonal
Ab 1418 is speciﬁc to parvovirus B19 and is used here as a negative control.
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Table 4
Relative afﬁnity binding of mAbs to recombinant gp120sa.
gp120 Clade Cameroon mAbs India mAbs
2557 2558 3694 3019 3869 4210 3074 3881 4508 4022 4490 4487 3906 4025 4121 4139 3791 3904
5-51 5-51 5-51 5-51 1-f 1-f 4-59 4-59 4-59 5-51 5-51 5-51 5-51 5-51 1-18 1-8 1-18 3-30 pb
Du151 C 0.026 0.010 0.042 0.020 0.013 0.064 0.028 0.010 0.024 0.003 0.012 0.024 0.025 0.010 0.075 0.045 0.024 0.020
Du156.12 C 0.010 0.005 0.005 0.001 0.027 0.025 0.019 0.005 0.011 0.002 0.010 0.019 0.017 0.008 0.009 0.027 0.013 0.002
Du422.1 C 0.006 0.003 0.007 0.002 0.019 0.010 0.018 0.004 0.006 0.001 0.007 0.017 0.008 0.006 0.011 0.022 0.007 0.003
ZM53M.PB12 C 0.006 0.006 0.003 0.006 0.008 0.009 0.013 0.002 0.006 0.001 0.008 0.011 0.012 0.004 0.006 0.007 0.002 0.002 0.529
Du172.17 C 0.017 0.009 0.018 0.001 0.024 0.021 0.024 0.009 0.017 0.003 0.021 0.028 0.021 0.014 0.045 0.024 0.009 0.007
C.ZA.1197MB C 0.009 0.004 0.007 0.001 0.020 0.014 0.015 0.004 0.015 0.001 0.014 0.016 0.068 0.005 0.018 0.023 0.009 0.002
ZM197M.PB7 C 0.017 0.006 0.007 0.005 0.019 0.012 0.017 0.004 0.030 0.003 0.038 0.030 0.012 0.021 0.040 0.027 0.003 0.005
92 RW020 A 0.030 0.016 0.006 0.001 0.033 0.029 0.033 0.008 0.021 0.002 0.008 0.018 0.029 0.005 0.009 0.023 0.010 0.003
SF162 B 0.058 0.011 0.009 0.004 0.031 0.025 0.019 0.160 – 0.001 0.008 0.011 0.020 0.004 0.014 0.023 – –
WITO4160 B 0.027 0.004 0.012 0.007 0.008 0.018 0.017 0.434 – 0.006 0.014 1.934 0.198 0.798 0.050 0.020 – –
TRO B 0.077 0.010 0.021 0.022 0.006 0.029 0.022 0.949 – 0.074 0.046 – – – 0.097 0.096 – –
JRFL B 0.018 0.008 0.008 0.002 0.019 0.016 0.072 – – 0.053 0.027 0.029 – – 0.174 – – –
PVO B 0.019 0.007 0.018 0.008 0.008 0.024 0.094 – – 0.003 0.032 0.032 0.023 0.008 – 0.072 – – 0.0002
REJO4541 B 0.020 0.009 0.026 0.009 0.009 0.631 0.022 – – 0.004 0.029 1.697 – 0.074 – – – –
SC422661.8 B 0.022 0.011 0.015 0.010 0.010 0.016 1.473 – – 0.024 0.009 0.013 0.024 0.076 – – – –
MN B 0.055 0.026 0.026 0.005 0.029 0.037 – – – 0.016 0.027 0.023 0.090 – 0.122 – – –
CDC451 B 0.011 0.259 0.008 – 0.050 – – – – – – – – – – – – –
11.B11.1550 B 0.137 0.296 – – – – – – – – – – – – – – – –
a Nine mAbs from each group (Cameroon and India) were tested by ELISA against 18 recombinant gp120s coated onto plastic plate at 1 mg/ml. All mAbs were titrated at
a concentration ranging from 10 to 0.00001 mg/ml (12 dilutions). At the top of each column the ID of the mAb is shown and immunoglobulin gene VH usage in the next row
below; VH5-51-derived mAbs from each panel are bold. The space separates gp120 clade C and A from clade B. The binding activity of V3 mAbs to gp120 is shown as 50% of
maximal binding and represents the relative afﬁnity. Human anti-parvovirus B19 mAb 1418 was used as a negative control and was not reactive (data not shown). Each
experiment was performed at least two independent times. —no reactivity (410.0).
b p — p Value was determined using the Chi-Squared longrank test; it indicates signiﬁcantly higher relative afﬁnities of Cameroonian compared to Indian mAbs for
binding to clade B gp120s.
Table 5
V3 sequences of recombinant gp120s tested in the binding assay.
gp120 Clade V3 sequencea
Consensus C CTRPNNNTRKSIRIGPGQTFYATGDIIGDIRQAHC
296 315 323a 331
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F317, suggesting that these two highly conserved residues on the
hydrophobic face of V3 (Gorny et al., 2011; Jiang et al., 2010) are
involved in the epitopes of 15mAbs. This conclusion is supported by
the fact that mutations at these two positions, in the gp120s of
CDC451 and 11.B11.1550 (Table 5) abrogated or substantially
reduced the binding of the majority of the mAbs (Table 4).Du156.12 C –––––––––––V–––––––––––––––––––––––
Du172.17 C ––––S––––––V––––––––F––––––––––––––
Du422.1 C –––––––––––V––––––––––––E––––––E–––
Du151 C ––––––––––––––––––––––––E–––N––E–––
ZM53M.PB12 C ––––G–––––––––––––A–F––TN––––––––Y–
C.ZA.1197MB C –––––––––––––––––––A––––NE––––––––Y–
ZM197M.PB7 C –V–––––––––V––––––––F–––E–––––––––––
92 RW020 A ––––––––––GV––––––A–––––G––––––––––
PVO B ––––––––––––S––––RA––––––––––––––––
SF162 B ––––––––––––T––––RA––––––––––––––––
TRO B –––––––––R––H––––RA––––––––––––––––
REJO4541 B ––––––––––––H–A––RA–––––E––––––K–Y–
WITO4160 B ––––G––––R––N––––RA–––––A––––––K–––
MN B –––––Y–K––R–H––––RA––T–KN–K–T––––––
SC422661.8 B ––––––––––G–T––––RV––*––E–V–––––V––
JRFL B ––––––––––––H––––RA––T––E––––––––––
CDC451 B ––––––H–––RVTL–––RVW–T––E–L–N––––––
11.B11.1550 B –I––––––––R–TM–––KVY–T––Q––––––––––
a The V3 loop sequences of gp120s were retrieved from the Los Alamos HIV-1
database and were aligned with consensus C V3 sequence (shown at the top) using
the seqpublish program (http://www.hiv.lanl.gov). The numbering of the V3
consensus C sequence corresponds to HXB2 gp160 position numbers 296-331
with a two residue deletion (310¼Q and 311¼R) and one residue insertion
(323a¼ I); this was determined using the HIV Sequence Locator program (http://
www.hiv.lanl.gov). To emphasize the numbering of V3 consensus C, the four
residues are underlined and numbered below: two cysteines (C) at positions 296
and 331, a glutamine (Q) at 315 and isoleucine (I) at 323a. The V3 crown is
comprised of approximately 13 amino acids (bold), to which all the mAbs bind.
The residues Arg (R ) and Lys (K) both at position 315 are present in the clade B
viruses and are bold and underlined. The hydrophobic residues I309 and F317 are
prerequisite for binding most of the mAbs tested; mutations in these positions,
bold and underlined, result in limited reactivity of gp120s with V3 mAbs.Discussion
Analysis of humanmAbs that display cross-neutralizing activity to
diverse HIV-1 subtypes is critical for gaining insight into the design of
a prophylactic vaccine. We previously showed that non-B clade anti-
V3 mAbs are more potent and cross-neutralizing than clade B derived
mAbs (Gorny et al., 2006). Notably, in the present study we found
that the neutralizing activity of mAbs derived from non-B clade-
infected individuals can be signiﬁcantly different depending on
whether the donor was infected by strains circulating in Cameroon,
mainly CRF02_AG or with strains circulating in India, mainly clade C
HIV-1. The greater neutralizing activity of the Cameroon-derived V3
mAbs was unexpected given the close resemblance of the consensus
V3 sequences between CRF02_AG and clade C viruses (only one
residue Ile is replaced by Val in the entire V3 sequence; yRKSI/
VRIGPGQy) and the conservation of the GPGQmotif in the V3 crown
of both clades.
Similarly, the Cameroon-derived mAbs were more potent than the
Indian-derived mAbs even when the mAbs were encoded by the
same VH5-51 and VL lambda genes. We have already observed that
human anti-V3 mAbs display biased usage of Ig genes, preferentially
using the pair of VH5-51 and VL lambda genes which is most likely
related to an antigen requirement (Gorny et al., 2011;2009). The
superior neutralizing activities of Cameroonian versus Indian V3
R. Andrabi et al. / Virology 439 (2013) 81–8886mAbs coded for by VH5-51/VL lambda genes suggest that this is
related to higher binding afﬁnity rather than different epitope
recognition since these mAbs have similar shape of the antigen-
binding site and bind the same V3 epitopes (Gorny et al., 2011; Jiang
et al., 2010). The binding studies conﬁrmed that relative afﬁnities of
Cameroonian compared to Indian V3 mAbs were signiﬁcantly higher
for binding to clade B gp120s and comparable with certain trends for
higher binding to clade C and A gp120s. Thus the mAbs from India
possibly did not mature as efﬁciently, resulting in their lower afﬁnity
and lower neutralizing activities. Lastly, it cannot be excluded that
host genetics contributed differently in regulating the virus-speciﬁc
antibody response in the two study populations.
Studies of the mutation rates are consistent with this hypothesis,
as the antibodies from India compared to those from Cameroon had a
lower percentage of mutations in the variable fragment of the heavy
and light chain genes, particularly in mAbs encoded by the same
VH5-51/VL lambda genes (though the difference did not reach
statistical signiﬁcance). Thus, it has been suggested that the percen-
tage of mutations in VH and VL may reﬂect afﬁnity maturation and
length of antigenic stimulation. For example, it was observed that
human anti-gp120mAbs produced from B cells derived from
recipients of a gp120 HIV-1 vaccine had 3.8% (range 0 to 8.2%) of
V(H) somatic mutations after six months of immunization (Moody
et al., 2012). In contrast, broadly neutralizing mAbs, which usually
appear after 2–3 years of HIV-1 infection, have 20%–35% of mutations
(Walker et al., 2011;2009; Wu et al., 2010). Another explanation may
be the greater range of V3 sequences that are found in AG-infected
individuals compared to clade C-infected individuals in which the V3
region is quite constant (Patel et al., 2008). Thus, antibody maturation
could reﬂect both length of antigenic stimulation and the diversity of
the antigen driving the immune response.
Given the similar recognition mode of the majority of the
mAbs described here, the question arose why mAbs from India,
even using the same VH5-51/VL lambda genes, have signiﬁcantly
lower neutralizing potency and relative afﬁnity compared to
those from Cameroon. The data suggest that V3 of clade C
compared to clade AG viruses have lower immunogenicity result-
ing from different V3 structures which impact the maturation of
anti-V3 antibodies.
This hypothesis is supported by two studies that analyzed the
conformation of the V3 loop in clade C viruses. It was shown that
intrinsic differences in V3 conformation exist between clade B
and C which are related to the sequence variability in the stem
and turn regions, but not in the base of the V3 loop (Patel et al.,
2008). Different V3 conformations may have consequences on the
antibody response, with less cross-reactivity and limited evolu-
tion of the V3 region in the clade C viruses towards evolving
X4-tropic variant loops (Patel et al., 2008). Indeed, clade C
envelopes carry a relatively conserved V3 sequence, and X4
variants of clade C evolve less frequently compared with clade B
(Morris et al., 2001; Peeters et al., 1999).
Another study visualized the dynamic 3D structure of the V3
crown by ab initio folding and suggested a rigid, not beta-hairpin-
like, structure of the V3 loop crown in the consensus cladeC V3
sequence compared to the ﬂexible beta-hairpin structure in
consensus clade B V3 (Almond et al., 2012). This conformational
alteration may impart immune evasion to the virus but, con-
versely, antibodies speciﬁc to consensus clade C V3 would be less
effective against other, more beta-hairpin-like strains.
In conclusion, it was found that human anti-V3 mAbs derived
from Cameroonian patients infected mainly with clade AG dis-
played higher relative binding afﬁnity to various recombinant
gp120s and signiﬁcantly higher neutralizing activities than V3
mAbs from Indian patients infected mostly by clade C HIV-1.
Particularly interesting is the fact that among anti-V3 mAbs
encoded by the VH5-51/VL lambda genes, those mAbs fromCameroon have a higher percentage of mutations and displayed
signiﬁcantly more efﬁcient neutralization than those from India.
These results suggest the clade C V3 region may have lower
immunogenicity compared to clade AG V3 loop from Cameroon
and its sequence can serve as a plausible template for vaccine
immunogen design.Materials and Methods
Monoclonal antibodies
Eighteen human anti-V3 mAbs developed from non-B clade
infected individuals living in Cameroon and India were used in
this study (Gorny et al., 2004;2009;2006). All donors were
chronically HIV-1 infected of unknown duration. Five of these
non-B clade V3 mAbs, 4139, 4210, 4487, 4490 and 4508 (Table 1),
were recently developed using cellular techniques as previously
described with some modiﬁcations (Gorny et al., 1991). Brieﬂy,
peripheral blood mononuclear cells (PBMC) were transformed
with Epstein-Barr virus (EBV) and cultured with a polyclonal B
cell activator, CpG (Traggiai et al., 2004) which enhances EBV
infection and B cell transformation. The culture supernatants
were screened for binding activity to V3-cholera toxin B (CTB)
fusion protein (Totrov et al., 2010) containing consensus V3
sequences from clade B and C. The reactive cells were fused with
the heteromyeloma cell line SHM-D33 (Teng et al., 1983) and the
resulting hybridoma cells that continued to make functional V3
Abs were repeatedly cloned until monoclonality was achieved.
In addition, one anti-V3 mAb 447-52D, generated from a clade
B infected individual (Gorny et al., 1993), and one control mAb,
1418, speciﬁc to parvovirus B19 (Gigler et al., 1999) were also
tested as controls (Table 1).
Envelope proteins
Seventeen recombinant gp120s representing sequences of
primary HIV-1 isolates from clade A, B and C (produced in 293
cells) were purchased from Immune Technology Corp. (http://
www.immune-tech.com); gp120MN (clade B) was purchased from
Immunodiagnostics, Inc. (Woburn, MA).
RT-PCR ampliﬁcation of the Ig variable region of the heavy and light
chain genes
The nucleotide sequence of the Ig variable genes and gene usage
by the newly developed human anti-V3 mAbs was determined as
previously described (Gorny et al., 2011;2009). Brieﬂy, messenger
RNA was extracted from the hybridoma cell lines producing anti-V3
mAbs and reverse transcribed into cDNA using oligo dT primer.
The variable domain of the heavy and lambda light chain genes
(VH and VL) was ampliﬁed from poly-C tailed cDNA by PCR using
deoxyinosine-containing anchor primer as the forward primer (Invi-
trogen) and gene speciﬁc primer as the reverse primer located in the
constant region of VH family genes, k and/or l genes. PCR ampliﬁca-
tion was performed using a cycling program and ethidium bromide-
stained 0.8% agarose gels were used to visualize the PCR products.
The bands of appropriate size were excised, puriﬁed and then cloned
into the 2.1-TOPO TA cloning vector (Invitrogen). For each chain, 6 to
12 independent clones were screened. The plasmids with the appro-
priate inserts were sequenced in both directions using the M13
primers. All sequencing reactions were performed at the Macrogen,
Rockville, MD. The sequence data were analyzed using Pregap4,
BioEdit softwares and the International ImMunoGene Tics (IMGT)
information system (http://imgt.cines.fr).
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The binding activity of the anti-V3 mAbs against the gp120s
was tested by ELISA as described (Gorny et al., 1997). Brieﬂy,
ELISA plates were coated overnight with gp120s at 1.0 mg/ml,
blocked with 2% bovine serum albumin in PBS, and then incu-
bated with mAbs at a concentration ranging from 10 to
0.00001 mg/ml. The bound mAbs were detected by incubation
with alkaline phosphatase-conjugated goat anti-human IgG
(g speciﬁc) (SouthernBiotech, Birmingham, AL) followed by add-
ing substrate to develop color and the plates were read at 410 nm.
The relative afﬁnities of mAb binding to gp120s were determined
by measuring the concentration of mAbs required for 50%
maximal binding deﬁned when the binding curve reached the
saturation level as described (Gorny et al., 2000).
TZM-bl neutralization assay
The anti-V3 mAbs were tested for neutralizing activities
against 41 psVs using the TZM-bl cell line as target cells, as
described (Li et al., 2005; Seaman et al., 2010). Pseudoviruses
expressing single cloned envelopes (Env) derived from tier 1
and tier 2 viruses were classiﬁed as neutralization-sensitive and
-resistant, respectively. Brieﬂy, 2-fold serial dilutions of mAbs,
starting from 50 mg/ml, were pre-incubated with the psVs and the
mAb/virus mixtures were incubated 48 h with TZM-bl cells
expressing CD4, CXCR4 and CCR5. The virus infectivity was
determined by measuring the luciferase activity in the cell
lysates. The 50% inhibitory concentration of mAb (IC50) was
determined at which relative luminescence units were reduced
50% compared to virus control wells.
Statistical analysis
A Chi-Squared test was used for analysis of the binding data and
the neutralizing IC50 values of two panels of anti-V3 mAbs, including
the separate analysis of tier 1, tier 2, clade B, non-clade B psVs, as well
as VH5-51 and non-VH5-51 encoded V3 mAbs. Because some of the
mAb/psV or mAb/gp120 combinations failed to react, the neutralizing
IC50 and relative afﬁnity data was treated as censored data and
therefore the Chi-Squared longrank test was used. The Student’s t-test
was used for analysis of mutation rates and relative afﬁnity of V3
mAbs binding to individual gp120s.
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